Biogen Inc. (Nasdaq: BIIB) presented Phase 2 data from its CELIA study evaluating diranersen, an investigational antisense oligonucleotide therapy targeting ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA